# VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

> **NCT01390545** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 300 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Veltuzumab

## Key facts

- **NCT ID:** NCT01390545
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 300 (ESTIMATED)
- **Why stopped:** Trial re-design; no safety issues identified
- **Last updated:** 2016-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01390545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01390545, "VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01390545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*